• Q3 net sales (-1% cc[2] and USD) broadly in line with prior year due to strong performance of Growth Products
    • Gilenya (USD 790 million, +15% cc) continued double-digit growth
    • Cosentyx (USD 301 million) on track for blockbuster status in first full year after approval
    • Oncology growth drivers including Tafinlar + Mekinist (USD 172 million, +29% cc), Promacta/Revolade (USD 168 million, +44% cc) and Jakavi (USD 149 million, +47% cc)
    • Sandoz Biopharmaceuticals[1] (USD 262 million, +41% cc) …